Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 19;195(3):263–274. doi: 10.1007/s10549-022-06698-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Distribution of pathologically confirmed HER2+ patients of the NBRST trial [18–20] based on the BluePrint single and dual subtype classification and their treatment response (N = 253). Patients are grouped based on their therapy regimen [chemotherapy (C) plus Trastuzumab (T) (panel a) or C + T and Pertuzumab (P) (panel b)], and their HR and HER2 status (HR+ HER2 + or HR- HER2+. The colored bars represents if a tumor did (pCR, blue) or did not [Residual Disease (RD), bisque] achieve pathological complete response (pCR). p-value determined with a chi-square test of independence between subtypes. Of the entire NBRST set (n = 289), 253 samples are showed due to low numerosity of HER2-Basal-type (n = 19) and Luminal-HER2-Basal (n = 17)